Efficacy of Intra-auricular Tranexamic Acid in Total Knee Arthroplasty

Sponsored by Centre Hospitalier de Montauban

About this trial

Last updated 6 years ago

Study ID

CHM

Status

Completed

Type

Interventional

Phase

Phase 4

Placebo

Accepting

18+ Years

All Sexes

Trial Timing

Ended 6 years ago

What is this trial about?

Tranexamic acid an antifibrinolytic that develops its anti-haemorrhagic action by inhibiting fibrinolytic activities of plasmin and many studies confirms its effectiveness in decreasing blood loss. The aim of this study was to observe postoperative bleeding with combined intravenous and per - os administration with two intra - articular doses (1 g and 2 g) of tranexamic acid in adult patients undergoing unilateral total knee replacement.

What are the participation requirements?

Inclusion Criteria

- Adult patients undergoing unilateral total knee replacement

Exclusion Criteria

* Absence of consent

* Tranexamic acid allergy

* Coagulopathy (preoperative platelet count <150,000 / mm3, INR [international normalized ratio]> 1.4, or prolonged partial thromboplastin time> 1.4 times normal),

* History of arterial or venous thromboembolic disease (cerebrovascular accident, deep vein thrombosis or pulmonary thromboembolism),

* Hematological disorder (a hematopoietic, hemorrhagic or thrombogenic disease),

* Retinopathy (severe limitation of the field of vision and / or color distortion),

* Refusal to receive blood products

* Pregnancy

* History of convulsions

* Participation in another clinical trial.